Both clinical relevant non-selective pharmacological HIF-1α inhibitors, 2-methoxyestradiol and digoxin, attenuate AngII- and oxPAPC-induced MMP-2 and MMP-9 expressions in vivo and AngII-induced AAA formation in vivo. The gene discussed is MMP9; the disease is triple-A syndrome.